B of A Securities Maintains Underperform on Moderna, Raises Price Target to $38

Benzinga Newsdesk www.benzinga.com Positive 63.5%

Neg 0% Neu 0% Pos 63.5%

B of A Securities analyst Dimple Gosai maintains Moderna (NASDAQ:MRNA) with a Underperform and raises the price target from $34 to $38.